Abstract
D-RNAi (Messenger RNA-antisense DNA interference), a novel posttranscriptional phenomenon of silencing gene expression by transfection of mRNA-aDNA hybrids, was originally observed in the effects of bcl-2 on phorbol ester-induced apoptosis in human prostate cancer LNCaP cells. This phenomenon was also demonstrated in chicken embryos and a human CD4+ T cell line, H9. The in vivo transduction of β-catenin DRNAi was shown to knock out more than 99% endogenous β-catenin gene expression, while the in cell transfection of HIV-1 D-RNAi homolog rejected viral gene replication completely. D-RNAi was found to have long-term gene knockout effects resulting from a posttranscriptional gene silencing mechanism that may involve the homologous recombination between intracellular mRNA and the mRNA components of a D-RNAi construct. These findings provide a potential intracellular defense system against cancer and viral infections.
Current Cancer Drug Targets
Title: D-RNAi (Messenger RNA-antisense DNA Interference) as a Novel Defense System Against Cancer and Viral Infections.
Volume: 1 Issue: 3
Author(s): Shi-Lung Lin and Shao-Yao Ying
Affiliation:
Abstract: D-RNAi (Messenger RNA-antisense DNA interference), a novel posttranscriptional phenomenon of silencing gene expression by transfection of mRNA-aDNA hybrids, was originally observed in the effects of bcl-2 on phorbol ester-induced apoptosis in human prostate cancer LNCaP cells. This phenomenon was also demonstrated in chicken embryos and a human CD4+ T cell line, H9. The in vivo transduction of β-catenin DRNAi was shown to knock out more than 99% endogenous β-catenin gene expression, while the in cell transfection of HIV-1 D-RNAi homolog rejected viral gene replication completely. D-RNAi was found to have long-term gene knockout effects resulting from a posttranscriptional gene silencing mechanism that may involve the homologous recombination between intracellular mRNA and the mRNA components of a D-RNAi construct. These findings provide a potential intracellular defense system against cancer and viral infections.
Export Options
About this article
Cite this article as:
Shi-Lung Lin and Shao-Yao Ying , D-RNAi (Messenger RNA-antisense DNA Interference) as a Novel Defense System Against Cancer and Viral Infections., Current Cancer Drug Targets 2001; 1 (3) . https://dx.doi.org/10.2174/1568009013334151
DOI https://dx.doi.org/10.2174/1568009013334151 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mesothelioma - Update on Management
Current Respiratory Medicine Reviews Structure Based Functional Annotation of Putative Conserved Proteins from Treponema pallidum: Search for a Potential Drug Target
Letters in Drug Design & Discovery Recent Development and Future Prospects of Molecular Targeted Therapy in Prostate Cancer
Current Molecular Pharmacology Effect of two Antiandrogens as Protectors of Prostate and Brain in a Huntington`s Animal Model
Anti-Cancer Agents in Medicinal Chemistry Sp/KLF Family and Tumor Angiogenesis in Pancreatic Cancer
Current Pharmaceutical Design Editorial [Hot topic:Food Addiction & Obesity Treatment Development (Executive Guest Editors: Mark S. Gold and Noni A. Graham)]
Current Pharmaceutical Design Design and Biological Evaluation of 3-Aryl-4-alkylpyrazol-5-amines Based on the Target Fishing
Current Computer-Aided Drug Design Editorial {Hot topic: QSPR Models for Computer-Aided Drug Design in Microbiology, Parasitology, and Pharmacology (Guest Editor: Humberto Gonzalez-Diaz)]
Current Computer-Aided Drug Design Immunotherapy of Melanoma
Current Molecular Pharmacology siRNA Therapy, Challenges and Underlying Perspectives of Dendrimer as Delivery Vector
Current Pharmaceutical Design Factors Affecting Quantification in PET/CT Imaging
Current Medical Imaging Genetic Association of CUGBP2 and DNMBP with Alzheimer’ s Disease in the Chinese Han Population
Current Alzheimer Research Volatile Disease Biomarkers in Breath: A Critique
Current Pharmaceutical Biotechnology Editorial (Thematic Issue: Chemoinformatics Models for Pharmaceutical Design, Part 2)
Current Pharmaceutical Design Targeting the Fibroblast Growth Factor Receptors for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Bladder Cancer and Stem Cells
Current Signal Transduction Therapy Predicting Cancer-Related MiRNAs Using Expression Profiles in Tumor Tissue
Current Pharmaceutical Biotechnology Functional Interplay between RNA-Binding Protein HuR and microRNAs
Current Protein & Peptide Science The Changing Face of HDAC Inhibitor Depsipeptide
Current Cancer Drug Targets BK Channel Modulators: A Comprehensive Overview
Current Medicinal Chemistry